Benzinga | Jun 11, 2021 07:02AM EDT

RBC Capital Maintains Outperform on Vertex Pharmaceuticals, Lowers Price Target to $242

RBC Capital analyst Brian Abrahams maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Outperform and lowers the price target from $262 to $242.